Last progress March 18, 2025 (10 months ago)
Introduced on March 18, 2025 by Nicole Malliotakis
Creates a framework for the President, working with the U.S. Trade Representative, to negotiate “trusted trade partner” agreements with foreign governments to secure, diversify, and speed delivery of medical goods. The agreements can include commitments on manufacturing, regulatory alignment, information‑sharing, tariff/duty treatment, and supply‑chain transparency; Congress gets advance notice, a time‑bound review and the ability to block agreements; the USTR must monitor partner compliance and the President must act quickly on reported violations.
The COVID–19 pandemic created significant demand pressures on the global medical supply chain.
A December 2020 report by the United States International Trade Commission found global demand exceeded available supply of many goods critical to the COVID–19 response; U.S. health care providers had trouble obtaining enough of those goods. The report also noted foreign export restrictions on finished drugs and active pharmaceutical ingredients may have stressed supplies of some critical COVID–19 treatment drugs (including anti‑infective products), hormone medications, and vitamins.
The McKinsey Global Institute reported that, over the 20 years before this Act, pharmaceutical supply chains became more globally dispersed and many generic small‑molecule products moved to lower‑cost production locations; some of those locations have been identified as posing a threat to U.S. national security.
The Organisation for Economic Co‑operation and Development (OECD) found the United States is both one of the largest exporters and one of the largest importers of COVID–19 critical goods.
The World Trade Organization found that while the United States, Germany, and the People’s Republic of China are major producers and importers of COVID–19 critical goods, U.S. import partners are less diversified. More than half of U.S. imports of COVID–19 critical goods came from only three partners: the People’s Republic of China (30.6 percent), Mexico (15.3 percent), and Malaysia (9.0 percent).
Primary affected groups
Pharmaceutical and medical technology companies: The bill creates new opportunities and constraints. Companies could gain more predictable market access and regulatory alignment with trusted partners, and faster cross‑border movement for critical goods; they may also face new information‑sharing or sourcing expectations under partner agreements.
Medical device manufacturers and importers: Could benefit from harmonized regulation and expedited customs processes, but may be required to disclose supply‑chain details and meet security or localization commitments tied to trusted partner arrangements.
Hospitals and other health care providers: Intended beneficiaries; the law aims to reduce supply disruptions and improve reliability of essential medical products and surge capacity during emergencies.
Shipping, freight forwarding, and logistics companies: May be affected by commitments to expedite movement of critical medical items and by any agreed customs facilitation measures (faster processing, prioritized lanes), increasing demand for compliant logistics services but also adding compliance requirements.
Federal trade and health agencies (USTR, HHS/FDA, DHS/CBP, Commerce, International Trade Commission): Increased workload to negotiate, vet partners against statutory factors, provide regular reports to Congress, monitor compliance, and support enforcement actions.
Broader effects and risks
Foreign governments that become “trusted partners” will face new obligations (regulatory cooperation, information sharing, IP protections) and monitoring; noncompliance can trigger suspension or remedial measures, affecting bilateral trade and diplomacy.
Supply‑chain resilience: If effectively implemented, the law can diversify sourcing, reduce single‑point dependencies, and improve emergency response through prearranged commitments, stockpiles, or surge manufacturing arrangements.
Costs and administrative burden: Negotiations, monitoring, and compliance activities create administrative and potential cost burdens for agencies, partner governments, and private sector firms (e.g., reporting, audits, verification). The bill itself does not appropriate funds, so agencies may need resources to implement new duties.
Trade and diplomatic tensions: Making eligibility conditional on security, legal, and compliance criteria could strain relations with excluded suppliers and prompt retaliatory measures in some cases; tariff/duty treatment changes could also raise trade policy debates.
Intellectual property and technology transfer tradeoffs: The bill balances protecting IP with encouraging production capacity abroad; partners may be asked to protect technology, but some production diversification may still require limited tech‑transfer or licensing arrangements, which can be politically sensitive.
Net effect
Referred to the Committee on Ways and Means, and in addition to the Committee on Rules, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Updated 1 day ago
Last progress March 12, 2025 (10 months ago)
